Short answer
Pacira BioSciences, Inc. (PCRX) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $192M (up 6.2% year over year) with net income of $5M.
Q2 2026 key financials · XBRL
- Revenue
- $192M
- +6.2% YoY · +8.5% QoQ
- Net income
- $5M
- +196.0% YoY · +59.6% QoQ
- Operating margin
- 2.2%
- EPS (diluted)
- $0.12
- +220.0% YoY · +71.4% QoQ
Source: XBRL data from the Pacira BioSciences, Inc. (PCRX) Q2 2026 10-Q on SEC EDGAR. USD.
Pacira BioSciences, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- iovera° divestiture closed July 31, 2026, generating $73.6 million cash proceeds
- Tariffs expected to pressure gross margins, including 15% on certain E.U. imports and 10% on U.K. imports
- PCRX-201 ASCEND Part A enrollment completed, with topline data expected by year-end 2026
- EXPAREL separate reimbursement expanded to approximately 150 million U.S. covered lives
Risk Factors
- New divestiture risk triggered by iovera° sale to Zimmer, including transition, indemnification, and contractual liabilities
- Most material update: potential milestone payments of $70.0 million depend on Zimmer’s performance and expire December 31, 2031
- Regulatory and commercial risk: milestone achievement depends on clinical and regulatory outcomes for iovera° products
- Operational risk: divestiture could divert management attention, disrupt operations, or increase costs
- Financial risk: failure to realize divestiture benefits or milestone payments could materially impair cash flows
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Pacira BioSciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.